Share the post "JUBILANT PHARMOVA : Q4 2024 Financial Quarterly Report : YoY Sales Down 89.52 %, QoQ Down 89.51 %"
Highlights
- Sales over the Year and quarter: The company’s sales declined by -89.52 % over the year, decrease in net sales/revenue by -89.51 %.
- Income over the Year and quarter: There has been decline in other income over the past year which is -91.59 %, Marginal decrease of -96.36% in other income during this quarter.
- Profit over the Year and quarter: Challenges in sustaining profitability for JUBILANT PHARMOVA LIMITED. Profit dropped by -93.85 % Year to Year, JUBILANT PHARMOVA LIMITED’s profitability dropped by -109.31 % Quarter to Quarter.
- EPS over the Year and quarter: EPS declined by -40.00 % Year to Year. EPS decreased by -187.44 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 1678 Cr | Rs. 1677.1 Cr | Rs. 175.86 Cr | -89.51 % | -89.52 % |
| Expenses | Rs. 1458.78 Cr | Rs. 1459.1 Cr | Rs. 148.72 Cr | -89.81 % | -89.81 % |
| Operating Profit | Rs. 219.22 Cr | Rs. 218 Cr | Rs. 27.14 Cr | -87.55 % | -87.62 % |
| OPM % | 13.06 % | 13 % | 15.43 % | + 2.43 % | + 2.37 % |
| Other Income | Rs. 21.16 Cr | Rs. 48.9 Cr | Rs. 1.78 Cr | -96.36 % | -91.59 % |
| Interest | Rs. 55.56 Cr | Rs. 71.3 Cr | Rs. 7.3 Cr | -89.76 % | -86.86 % |
| Depreciation | Rs. 271.23 Cr | Rs. 94.6 Cr | Rs. 10.1 Cr | -89.32 % | -96.28 % |
| Profit before tax | Rs. -86.41 Cr | Rs. 101 Cr | Rs. 11.52 Cr | -88.59 % | + 113.33 % |
| Tax % | -13.67 % | 39.36 % | -14.19 % | -53.55 % | -0.52 % |
| Net Profit | Rs. -100.51 Cr | Rs. 66.4 Cr | Rs. -6.18 Cr | -109.31 % | + 93.85 % |
| EPS in Rs | Rs. -6.15 | Rs. 4.2 | Rs. -3.68 | -187.62 % | + 40.16 % |
Today, we’re looking at JUBILANT PHARMOVA LIMITED’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -89.52 %. However, it did see a marginal slip of -89.51 % from the previous quarter. Expenses decreased slightly by -89.81 % quarter-on-quarter, aligning with the annual decline of -89.81 %. Operating profit, while down -87.62 % compared to last year, faced a quarter-on-quarter dip of -87.55 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 2.37 %, but an expansion of 2.43 % sequentially. Other income fell by -96.36 % compared to the last quarter, despite an annual decline of -91.59 %. Interest expenses dropped significantly by -89.76 % from the previous quarter, yet the year-over-year decrease remains at a moderate -86.86 %. Depreciation costs fell by -89.32 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -96.28 %. Profit before tax grew annually by 113.33 % but saw a reduction from the preceding quarter by -88.59 %.
Tax expenses as a percentage of profits decreased slightly by -0.52 % compared to last year, with a more notable quarter-on-quarter decrease of -53.55 %. Net profit rose by 93.85 % year-on-year but witnessed a -109.31 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 40.16 % but a quarterly fall of -187.62 %. In summary, JUBILANT PHARMOVA LIMITED’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 1678 Cr | Rs. 1677.1 Cr | Rs. 175.86 Cr | -89.51 % | -89.52 % |
| Expenses | Rs. 1458.78 Cr | Rs. 1459.1 Cr | Rs. 148.72 Cr | -89.81 % | -89.81 % |
| Operating Profit | Rs. 219.22 Cr | Rs. 218 Cr | Rs. 27.14 Cr | -87.55 % | -87.62 % |
| Net Profit | Rs. -100.51 Cr | Rs. 66.4 Cr | Rs. -6.18 Cr | -109.31 % | + 93.85 % |
| EPS in Rs | Rs. -6.15 | Rs. 4.2 | Rs. -3.68 | -187.62 % | + 40.16 % |
In reviewing JUBILANT PHARMOVA LIMITED’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -89.52 % year-on-year, although there was a slight dip of -89.51 % from the previous quarter. Expenses decreased by -89.81 % compared to the previous year, with a decrease of -89.81 % quarter-on-quarter. Operating Profit dropped by -87.62 % annually, and saw a -87.55 % decrease from the last quarter.
Net Profit showed yearly increase of 93.85 %, and experienced a -109.31 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 40.16 % annually, however dipped by -187.62 % compared to the last quarter. In essence, while JUBILANT PHARMOVA LIMITED exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
-47
3-Year Profit
-27
5-Year Profit
-18
10-Year Profit
1,115
Current Price
17,762
Market Cap
In analyzing the financial results for the company marked by BSE code 530019, a clear trend emerges. Over a five-year span, the company reported a profit of -27 percents, which increased to -47 percents in the most recent three-year period, suggesting a strong performance in the early stages of this timeframe. However, this success has been overshadowed by a trailing twelve-month (TTM) loss of -46 percents, signaling significant recent challenges. Compounding this issue is the fact that the company has not reported any sales during any of the timeframes analyzed, raising important questions about its operational model and the sustainability of its current strategies. Investors have been equally wary, as reflected in the stock price performance. The company’s stock traded at 21 percents over the past five years but has recently decreased to 162 percents, indicating a loss of market confidence. Over the last decade, the stock price was at 23 percents, pointing to longer-term concerns that could affect the company's future prospects.
Currently valued at ₹17,762 crore, the company's stock price stands at ₹1,115. Over the years, it has seen significant fluctuations, with its price ranging from ₹1,247 / 319, a reflection of its sensitivity to market conditions and investor sentiment. The stock's Price-to-Earnings (P/E) ratio, currently at 75.8, suggests that it is highly valued in comparison to its earnings, possibly indicating strong future growth expectations or a high level of investor confidence. The book value per share is ₹341, which represents the net asset value of the company per share. The dividend yield of 0.46% provides some return to investors, though it may not be the primary attraction for those investing in the stock. The company's Return on Capital Employed (ROCE) is 6.74%, pointing to efficient use of its capital base to generate profits. The Return on Equity (ROE), at 0.76%, highlights the profitability for shareholders. The company's financial health is further underscored by its very low debt-to-equity ratio of 0.67, signaling conservative financial management. However, the net cash flow is negative at ₹-57.5 crore, indicating possible liquidity concerns or heavy investment. The Piotroski score of 8.00 provides a snapshot of its financial stability, while the Graham Number, estimated at ₹516, offers an intrinsic value benchmark. With a Price-to-Book (P/B) ratio of 3.26, the stock seems to be trading at a premium relative to its book value, which could signal strong market expectations or overvaluation risks.
